Shenzhen Kangernuo Biotechnology

Shenzhen Kangernuo Biotechnology is a clinical-stage biotechnology company headquartered in Shenzhen, China, dedicated to the advancement of next-generation immune cell therapies. The company primarily focuses on developing Chimeric Antigen Receptor T-cell (CAR-T) therapies, with a strategic emphasis on off-the-shelf universal CAR-T (UCAR-T) products to overcome the limitations of autologous treatments. Its lead programs target hematological malignancies, including B-cell lymphoma and multiple myeloma, utilizing multi-target approaches to reduce tumor escape. Kangernuo leverages proprietary gene-editing and cell-expansion technologies to enhance the safety and scalability of its therapeutic pipeline.